Vergelijking

Buserelin vs. Glepaglutide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

57982-77-1

geen gegevens

Molecuulmassa

1239.42 g/mol

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Buserelin	Glepaglutide
Duitsland	Op recept	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Buserelin

Volledige vermelding →

Glepaglutide

Volledige vermelding →

Frequently asked questions

What is the difference between Buserelin and Glepaglutide?: Buserelin is classified as "Onderzoek (overig)", while Glepaglutide is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Glepaglutide?: The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Glepaglutide in Germany and the United States?: Duitsland: Buserelin — Op recept, Glepaglutide — Niet goedgekeurd. Verenigde Staten: Buserelin — Niet goedgekeurd, Glepaglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Glepaglutide

Duitsland

Op recept

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Buserelin and Glepaglutide?

Buserelin is classified as "Onderzoek (overig)", while Glepaglutide is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Glepaglutide?

The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Glepaglutide in Germany and the United States?

Duitsland: Buserelin — Op recept, Glepaglutide — Niet goedgekeurd. Verenigde Staten: Buserelin — Niet goedgekeurd, Glepaglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.